

July. 29, 2024

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

**Commencement of dosing therapeutic antibody drug conjugate, ADCT-701
in Phase I clinical study**

Chiome Bioscience Inc. (“Chiome”) announced today that the first patient was dosed (FPI: First Patient In) in a Phase I clinical study of the antibody drug conjugate ADCT-701 (which contains Chiome’s LIV-1205 antibody) that is being sponsored and conducted by the NCI (National Cancer Institute) of the National Institutes of Health in the USA.

ADCT-701 is an ADC (Antibody-Drug-Conjugate) that combines LIV-1205, a cancer therapeutic antibody developed by Chiome, with PBD (low molecular weight drug Pyrrolobenzodiazepine). The NCI is sponsoring and conducting a first-in-human Phase I clinical trial of ADCT-701 in patients with neuroendocrine tumors and carcinomas (NCT06041516). This study aims to determine the maximum tolerated dose and to evaluate safety and pharmacokinetics of ADCT-701 in patients with neuroendocrine tumors and carcinomas, which are rare forms of cancer. The study is currently underway at the NCI and the first patient has been dosed.

<About ADC>

ADCs are antibody-drug conjugates composed of an antibody bound to a small molecule, such as an anticancer drug (payload) via a linker. By binding a payload that specifically binds to a protein (antigen) that is a target for a specific type of cancer, the conjugate will selectively reach lesion sites and kill cancer cells. Because of target selectivity and high efficacy, ADCs are attracting attention as a next-generation drug that combines the best aspects of both antibody and small molecule therapeutics. More than 10 ADC products have been approved by the FDA.

<About LIV-1205>

LIV-1205 is a humanized monoclonal antibody binding to DLK-1 (Deltalike 1 homolog), which is an antigen (target molecule) expressed on the cell surface of solid tumors, mainly hepatocarcinoma. It inhibits the growth activity of the cancer. DLK-1 is thought to control the proliferation and differentiation of immature cells such as stem cells and progenitor cells. It is expressed on the surface of hepatocarcinoma cells and found to be related to its proliferation; therefore, DLK-1 is thought to be a target of new cancer treatment.

【Inquiries】

Chiome Bioscience Inc. Investor Relations

E-mail : ir@chiome.co.jp

For Patients Interested in Enrolling in NCT06041516:

<https://clinicaltrials.gov/study/NCT06041516?term=jaydira%20del%20rivero&rank=1>

For more information on this clinical trial, please call NCI's toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), visit the website <https://trials.cancer.gov>, and/or email NCIMO_referrals@mail.nih.gov.